Blood lead level and kidney function in US adolescents: The third national health and nutrition examination survey

Archives of Internal Medicine

Volumn 170, Issue 1, 2010, Pages 75-82

  Fadrowski, Jeffrey J ^a,b,c   Navas Acien, Ana ^a,b,c   Tellez Plaza, Maria ^a,b,c,d   Guallar, Eliseo ^a,b,c,d   Weaver, Virginia M ^a,b,c   Furth, Susan L ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYSTATIN C; LEAD;

ADOLESCENT; ADOLESCENT HEALTH; ADULT; ARTICLE; ENVIRONMENTAL EXPOSURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LEAD BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNITED STATES;

ADOLESCENT; CHILD; CREATININE; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FUNCTION TESTS; LEAD; LEAD POISONING; LINEAR MODELS; MALE; NUTRITION SURVEYS; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 74549128533     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.417     Document Type: Article

References (80)

1. Agency for Toxic Substances and Disease Registry. Toxicological Profile for Lead. Atlanta, GA: US Department of Health and Human Services, Public Health Service; 2007.
2. Ekong EB, Jaar BG, Weaver VM. Lead-related nephrotoxicity: a review of the epidemiologic evidence. Kidney Int. 2006;70(12):2074-2084.
3. Khalil-Manesh F, Gonick HC, Cohen AH, et al. Experimental model of lead nephropathy, I: continuous high-dose lead administration. Kidney Int. 1992;41(5):1192-1203.
4. Steenland K, Selevan S, Landrigan P. The mortality of lead smelter workers: an update. Am J Public Health. 1992;82(12):1641-1644.
5. Inglis JA, Henderson DA, Emmerson BT. The pathology and pathogenesis of chronic lead nephropathy occurring in Queensland. J Pathol. 1978;124(2):65-76.
6. Wedeen RP, Malik DK, Batuman V. Detection and treatment of occupational lead nephropathy. Arch Intern Med. 1979;139(1):53-57.
7. Muntner P, Menke A, DeSalvo KB, Rabito FA, Batuman V. Continued decline in blood lead levels among adults in the United States: the National Health and Nutrition Examination Surveys. Arch Intern Med. 2005;165(18):2155-2161.
8. Staessen JA, Lauwerys RR, Buchet JP, et al; The Cadmibel Study Group. Impairment of renal function with increasing blood lead concentrations in the general population. N Engl J Med. 1992;327(3):151-156.
9. Payton M, Hu H, Sparrow D, Weiss ST. Low-level lead exposure and renal function in the Normative Aging Study. Am J Epidemiol. 1994;140(9):821-829.
10. Kim R, Rotnitsky A, Sparrow D, Weiss S, Wager C, Hu H. A longitudinal study of low-level lead exposure and impairment of renal function: the Normative Aging Study. JAMA. 1996;275(15):1177-1181.
11. Tsaih SW, Korrick S, Schwartz J, et al. Lead, diabetes, hypertension, and renal function: the Normative Aging Study. Environ Health Perspect. 2004;112(11):1178-1182.
12. Muntner P, He J, Vupputuri S, Coresh J, Batuman V. Blood lead and chronic kidney disease in the general United States population: results from NHANES III. Kidney Int. 2003;63(3):1044-1050.
13. Akesson A, Lundh T, Vahter M, et al. Tubular and glomerular kidney effects in Swedish women with low environmental cadmium exposure. Environ Health Perspect. 2005;113(11):1627-1631.
14. Yu CC, Lin JL, Lin-Tan DT. Environmental exposure to lead and progression of chronic renal diseases: a four-year prospective longitudinal study. J Am Soc Nephrol. 2004;15(4):1016-1022.
15. Lin JL, Lin-Tan DT, Hsu KH, Yu CC. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med. 2003;348(4):277-286.
16. Lin JL, Lin-Tan DT, Li YJ, Chen KH, Huang YL. Low-level environmental exposure to lead and progressive chronic kidney diseases. Am J Med. 2006;119(8):707.e1-707.e9.
17. de Burbure C, Buchet JP, Leroyer A, et al. Renal and neurologic effects of cadmium, lead, mercury, and arsenic in children: evidence of early effects and multiple interactions at environmental exposure levels. Environ Health Perspect. 2006;114(4):584-590.
18. Staessen JA, Nawrot T, Hond ED, et al. Renal function, cytogenetic measurements, and sexual development in adolescents in relation to environmental pollutants: a feasibility study of biomarkers. Lancet. 2001;357(9269):1660-1669.
19. Meyer PA, Pivetz T, Dignam TA, Homa DM, Schoonover J, Brody D; Centers for Disease Control and Prevention. Surveillance for elevated blood lead levels among children - United States, 1997-2001. MMWR Surveill Summ. 2003;52(10):1-21.
20. Preventing Lead Poisoning in Young Children: a Statement by the Centers for Disease Control. Atlanta, GA: Centers for Disease Control; 1991.
21. Increased Lead Absorption in Young Children: a Statement by the Centers for Disease Control. Atlanta, GA: Centers for Disease Control; 1975.
22. Canfield RL, Henderson CR Jr, Cory-Slechta DA, Cox C, Jusko TA, Lanphear BP. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med. 2003;348(16):1517-1526.
23. Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. Lead exposure and cardiovascular disease-a systematic review. Environ Health Perspect. 2007;115(3):472-482.
24. Lanphear BP, Hornung R, Khoury J, et al. Low-level environmental lead exposure and children's intellectual function: an international pooled analysis. Environ Health Perspect. 2005;113(7):894-899.
25. Groesbeck D, Kottgen A, Parekh R, et al. Age, gender, and race effects on cystatin C levels in US adolescents. Clin J Am Soc Nephrol. 2008;3(6):1777-1785.
26. Andersen TB, Eskild-Jensen A, Frokiaer J, Brochner-Mortensen J. Measuring glomerular filtration rate in children: can cystatin C replace established methods? a review. Pediatr Nephrol. 2009;24(5):929-941.
27. Filler G, Lepage N. Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Pediatr Nephrol. 2003;18(10):981-985.
28. Newman DJ. Cystatin C. Ann Clin Biochem. 2002;39(pt 2):89-104.
29. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473-2483.
30. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992;38(10):1933- 1953.
31. Madero M, Sarnak MJ, Stevens LA. Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Nephrol Hypertens. 2006;15(6):610-616.
32. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40(2):221-226.
33. Roos JF, Doust J, Tett SE, Kirkpatrick CM. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children: a meta-analysis. Clin Biochem. 2007;40(5-6):383-391.
34. Ylinen EA, Ala-Houhala M, Harmoinen AP, Knip M. Cystatin C as a marker for glomerular filtration rate in pediatric patients. Pediatr Nephrol. 1999;13(6):506-509.
35. Köttgen A, Selvin E, Stevens LA, Levey AS, Van Lente F, Coresh J. Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2008;51(3):385-394.
36. Miller DT, Paschal DC, Gunter EW, Stroud PE, D'Angelo J. Determination of lead in blood using electrothermal atomisation atomic absorption spectrometry with a L'vov platform and matrix modifier. Analyst. 1987;112(12):1701- 1704.
37. US Department of Health and Human Services. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III second laboratory data file. ftp://ftp.cdc.gov/pub/Health-Statistics/ NCHS/Datasets/NHANES/NHANESIII/2A/lab2-acc.pdf. Accessed June 8, 2009.
38. Hornung RW, Reed LD. Estimation of average concentration in the presence of nondetectable values. Appl Occup Environ Hyg. 1990;(5):546-551.
39. Gunter EW, Lewis BG, Koncikowski SM; US Department of Health and Human Services. Laboratory procedures used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. http://www.cdc.gov/nchs/data/ nhanes/nhanes3/cdrom/nchs/manuals/labman.pdf. Accessed April 1, 2009.
40. Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem. 1997;43(6, pt 1):1016-1022.
41. Schwartz GJ, Haycock GB, Spitzer A. Plasma creatinine and urea concentration in children: normal values for age and sex. J Pediatr. 1976;88(5):828-830.
42. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am. 1987;34(3):571-590.
43. Furth SL, Cole SR, Moxey-Mims M, et al. Design and methods of Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol. 2006;1(5):1006-1015.
44. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629-637.
45. United States Department of Agriculture. Economic Research Service. Rural-urban continuum codes. http://www.ers.usda.gov/Data/ RuralUrbanContinuumCodes/. Accessed February 3, 2009.
46. Centers for Disease Control and Prevention. Healthy weight, assessing your weight, body mass index. http://www.cdc.gov/healthyweight/assessing/bmi/ index.html. Accessed February 3, 2009.
47. Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev. 1996;18(2):188-204.
48. Pirkle JL, Bernert JT, Caudill SP, Sosnoff CS, Pechacek TF. Trends in the exposure of nonsmokers in the U.S. population to secondhand smoke: 1988-2002. Environ Health Perspect. 2006;114(6):853-858.
49. Lumley T. Survey: analysis of complex survey samples. R statistical software package, version 2.9.1 (2009-06-26). http://cran.r-project.org/web/ packages/survey. Accessed July 14, 2009.
50. National Center for Health Statistics. Centers for Disease Control and Prevention Web site. Documentation, codebook, and frequencies. Surplus sera laboratory component: cystatin C (Surplus Sera). Survey years 1988-1994. ftp://ftp.cdc.gov/pub/Health-Statistics/NCHS/Datasets/NHANES/NHANESIII/27a/ SSCYSTAT.pdf. Accessed February 3, 2009.
51. Pirkle JL, Kaufmann RB, Brody DJ, Hickman T, Gunter EW, Paschal DC. Exposure of the U.S. population to lead, 1991-1994. Environ Health Perspect. 1998;106(11):745-750.
52. National Center for Environmental Health. Third National Report on Human Exposure to Environmental Chemicals. Atlanta, GA: Centers for Disease Control and Prevention. 2005:38-44. NCEH Pub. No. 05-0570.
53. Levin R, Brown MJ, Kashtock ME, et al. Lead exposures in U.S. children, 2008: implications for prevention. Environ Health Perspect. 2008;116(10):1285-1293.
54. Lin C, Kim R, Tsaih SW, Sparrow D, Hu H. Determinants of bone and blood lead levels among minorities living in the Boston area. Environ Health Perspect. 2004;112(11):1147-1151.
55. Lanphear BP, Burgoon DA, Rust SW, Eberly S, Galke W. Environmental exposures to lead and urban children's blood lead levels. Environ Res. 1998;76(2):120-130.
56. Oktem F, Arslan MK, Dundar B, Delibas N, Gultepe M, Ergurhan Ilhan I. Renal effects and erythrocyte oxidative stress in long-term low-level lead-exposed adolescent workers in auto repair workshops. Arch Toxicol. 2004;78(12):681-687.
57. Sönmez F, Dönmez O, Sönmez HM, Keskinoǧlu A, Kabasakal C, Mir S. Lead exposure and urinary N-acetyl β D glucosaminidase activity in adolescent workers in auto repair workshops. J Adolesc Health. 2002;30(3):213-216.
58. Fels LM, Wunsch M, Baranowski J, et al. Adverse effects of chronic low level lead exposure on kidney function: a risk group study in children. Nephrol Dial Transplant. 1998;13(9):2248-2256.
59. Verberk MM, Willems TE, Verplanke AJ, De Wolff FA. Environmental lead and renal effects in children. Arch Environ Health. 1996;51(1):83-87.
60. Bernard AM, Vyskocil A, Roels H, Kriz J, Kodl M, Lauwerys R. Renal effects in children living in the vicinity of a lead smelter. Environ Res. 1995;68(2):91-95.
61. Weaver VM, Lee BK, Ahn KD, et al. Associations of lead biomarkers with renal function in Korean lead workers. Occup Environ Med. 2003;60(8):551-562.
62. Weaver VM, Schwartz BS, Ahn KD, et al. Associations of renal function with polymorphisms in the delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead workers. Environ Health Perspect. 2003; 111(13):1613-1619.
63. Roels H, Lauwerys R, Konings J, et al. Renal function and hyperfiltration capacity in lead smelter workers with high bone lead. Occup Environ Med. 1994; 51(8):505-512.
64. Hsiao CY, Wu HD, Lai JS, Kuo HW. A longitudinal study of the effects of longterm exposure to lead among lead battery factory workers in Taiwan (1989-1999). Sci Total Environ. 2001;279(1-3):151-158.
65. Hu H. A 50-year follow-up of childhood plumbism: hypertension, renal function, and hemoglobin levels among survivors. Am J Dis Child. 1991;145(6):681-687.
66. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2)(suppl 1):S1-S266.
67. Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr. 1984;104(6):849-854.
68. Léger F, Bouissou F, Coulais Y, Tafani M, Chatelut E. Estimation of glomerular filtration rate in children. Pediatr Nephrol. 2002;17(11):903-907.
69. Ferguson MA, Vaidya VS, Bonventre JV. Biomarkers of nephrotoxic acute kidney injury. Toxicology. 2008;245(3):182-193.
70. Tenstad O, Roald AB, Grubb A, Aukland K. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest. 1996;56(5):409-414.
71. Norris KC, Agodoa LY. Unraveling the racial disparities associated with kidney disease. Kidney Int. 2005;68(3):914-924.
72. Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med. 1982;306(21):1276-1279.
73. McDonald SP, Russ GR, Kerr PG, Collins JF; Australia and New Zealand Dialysis and Transplant Registry. ESRD in Australia and New Zealand at the end of the millennium: a report from the ANZDATA registry. Am J Kidney Dis. 2002;40(6):1122-1131.
74. Lambie M, Richards N, Smith S. Ethnicity, age and incidence rates for renal replacement therapy (RRT) in Birmingham, UK: 1990-2004. Nephrol Dial Transplant. 2008;23(12):3983-3987.
75. Perkovic V, Cass A, Patel AA, et al; InterASIA Collaborative Group. High prevalence of chronic kidney disease in Thailand. Kidney Int. 2008;73(4):473-479.
76. Merkin SS. Exploring the pathways between socioeconomic status and ESRD. Am J Kidney Dis. 2008;51(4):539-541.
77. Ward MM. Socioeconomic status and the incidence of ESRD. Am J Kidney Dis. 2008;51(4):563-572.
78. Collins AJ, Foley RN, Herzog C, et al. United States Renal Data System 2008 Annual Data Report Abstract. Am J Kidney Dis. 2009;53(suppl 1):vi-vii, S8-S374.
79. Levey AS, Andreoli SP, DuBose T, Provenzano R, Collins AJ. CKD: common, harmful, and treatable; World Kidney Day 2007. Am J Kidney Dis. 2007;49(2):175-179.
80. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-2047.